Esperion Therapeutics ESPR Number of Vested and Expected to Vest Options
Number of Vested and Expected to Vest Options at other companies
Other financials
Where this comes from
Reported directly by Esperion Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue.
The official record: Esperion Therapeutics’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Esperion Therapeutics's number of vested and expected to vest options.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Esperion Therapeutics's number of vested and expected to vest options?
- Esperion Therapeutics (ESPR) reported number of vested and expected to vest options of $4.75M in Q1 2026.
- How has Esperion Therapeutics's number of vested and expected to vest options changed year-over-year?
- Esperion Therapeutics's number of vested and expected to vest options increased by 39500.0% year-over-year, from $12K to $4.75M.
- What is the long-term trend for Esperion Therapeutics's number of vested and expected to vest options?
- Over 2 years (2020 to 2025), Esperion Therapeutics's number of vested and expected to vest options has grown at a -34.1% compound annual growth rate (CAGR), from $18.42M to $8M.
- What does number of vested and expected to vest options mean?
- This represents the total count of share-based payment options that have either met vesting requirements or are anticipated to vest based on service conditions. It provides a quantitative view of the company's long-term incentive compensation structure. This metric is essential for calculating potential future dilution and assessing the scale of equity-based compensation.